Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
ARGX (argenx SE) – Technical Charts and Market Data – TrendSpider
ARGX-119 is an agonist antibody for human MuSK that reverses disease ...
slide5
GRAPHIC
ARGX-119 | MuSK Agonist | MedChemExpress
slide46
slide6
Vyvgart stuwt omzet naar recordhoogte bij argenx | Bolero
slide3
Agonist antibody to MuSK protects mice from MuSK myasthenia gravis | PNAS
argenx advances ARGX-119 in congenital myasthenic syndromes - Drug ...
[ARGX] アルジェンX 通期増収営業黒字転換 売上高90％増41.5億ドル、営業益10.5億ドル、EPS19.57ドル - 株探(かぶたん ...
ARGX-117-2002 on the App Store
argenx ARGX-113-2308 on the App Store
Argenx antibody kills AML - European Biotechnology Magazine
[ARGX] アルジェンX 1Q増収増益 売上高64％増12.9億ドル、営業益2.8倍3.94億ドル、EPS5.52ドル - 株探(かぶたん)｜米国株
slide14
NYU Langone Health Hosts Inaugural Innovators’ Dinner to Celebrate and ...
Chart of the Day: Argenx - Great Biotech - The Globe and Mail
Anti-C2 Antibody ARGX-117 Inhibits Complement in a Disease Model for ...
Anti-c-Met Antibody [ARGX-111] Biosimilar (A339585) | Antibodies.com
The NHance® Mutation-Equipped Anti-MET Antibody ARGX-111 Displays ...
Pipeline – Inspirna
RCSB PDB - 8ACF: Structure of the argX-117 in complex with a complement ...
PPD_ARGX-113-2315 on the App Store
RussellPask/Argx · Datasets at Hugging Face
slide32
Safety, Efficacy, And Pharmacokinetics of Argx-117 in Adults With ...
slide7
EDGAR Filing Documents for 0001558370-23-004027
argx-20250630_d2
Patient-specific therapeutic benefit of MuSK agonist antibody ARGX-119 ...
AAN
📢 Today, we announced our plan to advance the clinical development of ...
ARGX-119 Development - argenx Annual Report 2023
ARGX-119 | MuSK激动剂 | MCE
Argenx研发日：FcRn的无限迭代 Armstrong 2024年7月16日， Argenx 召开了2024年度研发日活动，系统介绍了临床 ...
ARGX-119(ARGX-119) - 药物靶点：MUSK_在研适应症：肌萎缩侧索硬化，先天性肌无力综合征，脊髓性肌萎缩_专利_临床_研发
argenx Advances Clinical Development of ARGX-119 in Congenital ...
煜森资本：大涨40%，VYVGART能否撑起Argenx300亿美元市值？_财富号_东方财富网
ARGX-117, a therapeutic complement inhibiting antibody targeting C2 - PMC
再鼎医药发现“金山”_财富号_东方财富网
Dividends and Other Distributions - argenx Annual Report 2024
Some people with MuSK MG may see muscle strength gains with ARGX-119
Biogenesis and sequence analysis of ArgX. (A) Schematic overview of the ...
Cure SMA Clinical TrialsTrial ID ARGX-119-24-SMA-2001
argenx SE (ARGX) Expands Autoimmune Leadership with Vyvgart Launch
Argenx SE 2017 Q4 - Results - Earnings Call Slides (NASDAQ:ARGX ...
骆驼科IgG1抗体发现平台：药物开发公司Argenx介绍 - 知乎
argenx SE (ARGX) Presents at 44th Annual J.P. Morgan Healthcare ...
ARGX-117, a therapeutic complement inhibiting antibody targeting C2 ...
Targeted 'biological missile' blocks leukemia growth while sparing ...
How The argenx (ENXTBR:ARGX) Narrative Is Shifting With Vyvgart Growth ...
Argenx (ARGX) Phase2 Study Of Efgartigimod In Patients With Generalized ...
Argenx SE (ARGX) Updates On Phase 2 Clinical Proof-of-Concept Trial of ...
Badanie bezpieczeństwa i skuteczności ARGX-119 u dorosłych pacjentów z ...
Estudio de seguridad y eficacia de ARGX-119 en pacientes adultos con ...
Biotech的暴力美学：一款大药，3000亿市值医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
argenx SE Investor Presentation Deck | Slidebook.io
argenx Advances ARGX-119 for CMS Treatment
乘胜追击！Argenx下一个催化剂：ARGX-117即将读出POC数据！医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Clinical Development of ARGX-119 for Congenital Myasthenic Syndromes ...
